INTRODUCTION
Inositol 1,4,5-trisphosphate (InsP3) is a final common modulator of the phosphoinositide second messenger system, triggering the release of intracellular Ca2+ in numerous tissues (for review, see [1, 2] ). InsP3 acts by binding to a receptor protein which has been shown by reconstitution experiments to contain both the recognition site for InsP3 and the associated Ca2+ channel [3] . Ca2+ is released by InsP3 from a non-mitochondrial pool associated with the endoplasmic reticulum [4] . In the brain, the InsP3 receptor has been shown by electron-microscopic immunohistochemistry to be localized to subdivisions of the rough and smooth endoplasmic reticulum as well as the nuclear membrane [5] . The InsP3 receptor purified from mammalian brain consists of 260 kDa monomers, with the native protein comprising a homotetramer [6] . The cDNA for the rat cerebellar InsP3 receptor protein has been cloned [7] . Very recently, the isolation and characterization of an InsP3 receptor from bovine aorta has been described [8] .
Although InsP3 binding sites were initially demonstrated both in peripheral tissues [9] [10] [11] [12] and in the brain [13, 14] , their great density in brain tissue, especially the cerebellum, resulted in a focus upon the brain as a source for purification and characterization of physiological InsP3 receptors. A growing body of evidence implicates InsP3 as a mediator of pharmacomechanical coupling in smooth muscle, although the role of InsP3 in skeletal and cardiac muscle contraction is still controversial (for reviews, see [15] [16] [17] ). Ca2+-induced Ca2+ release mediated via the ryanodine receptor junctional foot protein appears to be a major determinant of excitation-contraction coupling in skeletal and cardiac muscle (for reviews, see [18, 19] ). Interestingly, the cloned InsP3 receptor protein displays marked sequence similarity with the cloned ryanodine receptor protein [7, 20, 21] . We wondered whether InsP3 binding sites in peripheral tissues involve the same protein as in the brain or are different, conceivably more closely resembling ryanodine receptors. Be 
Preparation of membranes
Tissue from freshly killed male Sprague-Dawley rats (200-300 g) was homogenized (50 mg wet wt./ml of buffer) with a Brinkmann Polytron (setting 6; 10 s) at 4°C in buffer A containing 50 mM-Tris/HCl, pH 7.7, 150 mM-NaCl, I mm-EDTA, 1 mM-fl-ME, phenylmethanesulphonyl fluoride (100 ,ug/ml), N2-p-tosylarginine methyl ester (10 ,ug/ml) and leupeptin and aprotinin (each 5 jug/ml). Homogenates were centrifuged (15 min, 30000 g), the supernatants were discarded and the pellets were resuspended in the same volume of buffer. Homogenization, centrifugation and resuspension of the memVol. 272
Abbreviations used: Con A, concanavalin A; PKA, cyclic AMP-dependent protein kinase; PEG, poly(ethylene glycol); NEM, N-ethylmaleimide; #8-ME, /-mercaptoethanol. * To whom correspondence should be addressed. brane pellets were repeated twice to provide the washed membrane fraction.
13H-IInsP3 binding to membranes
InsP3 binding to washed membranes was measured essentially as described [14] . Binding reactions consisted of 200 ,ul of washed membranes, 5 nM-[3H]InsP3 and buffer A to a final volume of 0.5 ml. Reactions were incubated to equilibrium at 4°C for 10 min and terminated by centrifugation (5 min, 12000 g). Unbound ligand in the supernatant was removed by aspiration and bound radioactivity in the pellets was measured by liquid scintillation chromatography in 5 ml of Formula 963 following membrane pellet solubilization with 200 ,1 of 1 % SDS. Specific binding represented less than 10 % of added radioactivity. Nonspecific binding was determined in the presence of 5 ,UM unlabelled InsP3.
Purification of InsP3 receptor sites from vas deferens
The InsP3 binding site in rat vas deferens was purified by a procedure similar to the purification of the cerebellar InsP3 receptor [6] . Fresh rat vas deferens (10 g) was minced with a razor blade, and washed membranes were prepared as described above. All procedures were carried out at 4 'C. Membrane proteins were solubilized in Triton X-10 cdetergent (final concentration 1.5 %) with gentle stirring for 1 h followed by centrifugation (45 min, 45000 g). The supernatant was collected, adjusted to 0.25 M-NaCl and passed over a heparin-agarose column (7 ml packed volume) that had been equilibrated with buffer A containing 0.25 M-NaCl and 0.1 % Triton X-100. The column was washed twice with 5 column vol. of buffer A containing 0.25 M-NaCI/0. 1% Triton X-100 and eluted with 4 column vol. of buffer A/0.5 M-NaCI/0.1 % Triton X-100. The heparin eluate was adjusted to 1 mM-MgCl2 and 1 mM-CaCl2 and incubated with 3 ml of packed glutaraldehyde-fixed Con ASepharose for 1 h on a rotator. Glutaraldehyde fixation of the Con A-Sepharose prevents Con A leaching from the column [27] . After 1 h, the resin was poured into a column, washed twice with 5 column vol. of buffer A containing 0.5 M-NaCI/ 1 mMMgCl2/l mM-CaCl2/0.1% Triton X-100, and eluted batchwise for at least 2 h with 20 ml of buffer A containing 2 mM-EDTA, 1 M-a-methylmannoside and 0.1 % Triton X-100. The Con A eluate was diluted 5-fold with buffer A and applied to an analytical f.p.l.c. 5/5 Mono Q anion-exchange column at a flow rate of 1 ml/min. The column was washed with 5 bed vol. of buffer A and eluted with a linear gradient of 0-400 mM-NaCl at 0.5 ml/min. InsP3 binding activity reached a peak at 250-300 mMNaCl.
13HJInsP3 binding to the solubilized receptor InsP3 binding to detergent-solubilized fractions and purified InsP3 receptor was determined by poly(ethylene glycol) (PEG) precipitation assay as follows. Samples were incubated to equilibrium (10 min) at 4 'C with 5 nM-[3H]InsP3in a reaction volume of 0.5 ml. Protein containing bound InsP3 was precipitated with 50 ,u1 of 0.5 % y-globulin and 0.8 ml of ice-cold 30 % PEG. After an additional 7 min, the samples were centrifuged (10 min, 12000 g), supernatants were removed, the pellets were solubilized with 0.1 ml 1 % SDS and radioactivity was measured in 5 ml of Formula 963. Non-specific binding was determined in the presence of 5 #M unlabelled InsP3.
Assessment of calmedin activity
[3H]InsP3 binding was assayed as described above. Calmedin activity was measured according to Danoff et a!. [33] . Purified cerebellar or vas deferens InsP3 receptor was incubated with calmedin-enriched fractions (heparin flow-through, 100 #l) in (a) the absence of Ca2+, (b) the presence of 500 ftM-Ca2+ and (c) the presence of 500 /LM-Ca2+ followed by 15 min of treatment with 1 mM-EDTA. Calmedin activity is defined as the EDTAreversible Ca2+-dependent inhibition of [3H]InsP3 binding.
Other methods
Protein was determined by a modification of the Lowry method [28] . SDS/PAGE was performed by the method of Laemmli [29] , and the gels were stained with silver [30] . InsP3 5-phosphatase and InsP3 3-kinase activities were assayed as previously described [31] .
RESULTS

Tissue distribution and autoradiographic localization of InsP3 binding sites
In a screen of numerous rat tissues, highest levels of [3H]InsP3 binding occurred in the cerebellum (Table 1 ). Of 12 peripheral tissues examined, high binding levels were apparent in the vas deferens (25 % of cerebellum) and testis, with moderate levels in immune tissue (spleen and thymus), endocrine tissue (adrenal gland and pancreas), kidney and forebrain. Low levels of specific Binding sites were densely concentrated throughout the muscle layer, and substantial binding was evident in the epithelial layer adjacent to the lumen. No binding was apparent in the lamina propria or adventitia. Interestingly, substantial binding was evident in the smooth muscle layer of blood vessels of the adventitia surrounding the vas deferens.
Purification of InsP3 binding protein from the vas deferens
We purified an InsP3 binding site from rat vas deferens by a procedure resembling the protocol we employed previously in purifying rat cerebellar InsP3 receptor ( (Fig. 2) . Moreover, gel filtration revealed the same apparent molecular masses for the native proteins from cerebellum and vas deferens (Fig. 3) , slightly in excess of 1000 kDa. Vol. 272 previous separation of these enzymes from the brain InsP3 receptor [31] . Specifically, the InsP3 5-monophosphatase failed to adhere to the heparin column, and the InsP3 3-kinase did not adhere to the Con A-Sepharose column.
Properties of purified InsP3 receptor protein from vas deferens
Earlier, we observed a single homogeneous population of InsP3 binding sites in brain membranes and with purified cerebellar InsP3 receptor [6] . Mauger et al. [32] Heparin is a potent inhibitor of InsP3 binding to cerebellar receptors [14] . Heparin displayed about the same potency in inhibiting particulate and purified vas deferens as cerebellar receptors, with an IC,O (concn. causing 50 % inhibition) of approx. 5 ,ug/ml (Table 4) . As with the cerebellar receptor, InsP3 binding to the vas deferens receptor in particulate and purified preparations was inhibited by N-ethylmaleimide (NEM), with the inhibition reversed by fl-ME. Receptor binding in particulate and purified preparations of both vas deferens and cerebellum was abolished by heating for 1 h at 60°C and by trypsin treatment (Table 4) .
A striking property of the cerebellar InsP3 receptor is its sensitivity to physiological intracellular concentrations of Ca2+ in membranes and crude solubilized preparations, with 50 % inhibition of binding at 0.3 /SM-Ca2+ [14] . Purification of cerebellar InsP3 receptor protein results in a dramatic loss of sensitivity to inhibition of binding by Ca2 , with sensitivity being restored by a particulate protein activity designated 'calmedin' [33] . Weconfirmed the almost complete and reversible inhibition of cerebellar particulate InsP3 binding by 10 /SM-Ca2 , whereas the purified cerebellar receptor showed no inhibition with 1 mM-Caa21 (Table 4) . Surprisingly, the vas deferens particulate and purified InsP3 binding protein was resistant to inhibition by 1 mM-Ca2 .
Failure of Caa2+ to inhibit particulate InsP3 binding in vas deferens may reflect a lack of calmedin in peripheral tissues [33] or inability of the smooth muscle receptor to associate with calmedin. To address this issue, calmedin-enriched fractions [33] prepared from cerebrllum or vas deferens were added to purified cerebellar and vas deferens InsP3 receptors, and sensitivity to calcium-dependent inhibition of InsP3 binding was examined (Table 5 ). The calmedin-enriched fraction from vas deferens The cerebellar InsP3 receptor is highly sensitive to pH, with a doubling of InsP3 binding between pH 7.5 and 8.5 [14] . A similar pH-dependence of InsP3 binding at the purified vas deferens receptor was apparent (Fig. 5) [11] ), adrenal gland (5 nM, [9] ) and pituitary gland (1.5 nm, [12] Ferris & S. H. Snyder, unpublished work). Nunn et al. [37] have also identified a 260 kDa protein in liver and cerebellum using radiation inactivation. Thus in the rat we have little evidence for heterogeneity of the InsP3 receptor protein in any tissues. Chadwick et al. [8] recently purified and characterized an InsP3 receptor from bovine aorta. This protein has similar properties to the rat vas deferens InsP3 receptor, namely similar abundance, Kd, Bmax and inhibition by heparin. The bovine aorta InsP3 receptor has an apparently lower molecular mass (224 kDa) than the cerebellar and vas deferens InsP3 receptor (260 kDa). Possible explanations for discrepancies in molecular mass could be explained by species variations or differences in electrophoretic properties.
The substantial levels of nearly identical InsP3 receptor proteins in numerous peripheral tissues of the rat fit with the postulated role of InsP3 in regulating the activities of organs throughout the body, and suggest that similar molecular mechanisms of InsP3 action in releasing Ca2+ are involved in all tissues. Unlike the cerebellar InsP3 receptor, however, we did not see Ca2+-dependent inhibition of InsP3 binding to vas deferens membrane preparations. Similarly, Nahorski and associates [38] found no [15] [16] [17] . A similar role for the ryanodine receptor in smooth muscle is suggested by the ability of ryanodine to abolish phasic contractions of smooth muscle [24, 25] [40] . Such an interaction between InsP, and ryanodine receptors has been described by Iino et al. [24] . They [41] . Moreover, co-transmitter interactions of neurotransmitters, such as noradrenaline and ATP [42] , have been well delineated in the vas deferens.
